Solidly Positive Phase III Data Boost Keryx’ Struggling Iron Drug Auryxia
This article was originally published in The Pink Sheet Daily
Executive Summary
Keryx set to pursue expanded FDA labeling of its phosphate binder Auryxia to pre-dialysis patients with iron deficiency, a patient population already approved for treatment in Europe.
You may also be interested in...
Keeping Track: Arymo ER Approved, Parsabiv Returns, Merck Surprises With Keytruda Chemo Combo Submission
The latest drug development news and highlights from our FDA Performance Tracker.
Keryx Aims For Ironclad Hold On Hyperphosphatemia Market
Recently-approved (and still un-trade named) phosphate binder ferric citrate could unseat the market leader due to its unique ability to increase iron in patients, firm believes, although it didn’t get the full set of labeling claims it sought.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.